Aligos Therapeutics, Inc. (ALGS) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $698.18M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $437.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $696.58M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $438.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $695.27M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $468.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $9.00K; Additional Paid in Capital, Common StockUSD $693.69M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $455.00K.
Aligos Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $9.00K | $698.18M | $437.00K | $-666.75M | $31.88M | (m) | 3 month · $135.00K | 3 month · $1.23M | (m) | (m) |
| 2026-03-31 | $0.00 | $9.00K | $696.58M | $438.00K | $-665.24M | $31.79M | (m) | 3 month · $89.00K | 3 month · $1.23M | (m) | (m) |
| 2025-12-31 | $0.00 | $9.00K | $695.27M | $468.00K | $-642.20M | $53.55M | 12 month · $3.66M | 12 month · $503.00K | 12 month · $4.54M | (m) | (m) |
| 2025-09-30 | $0.00 | $9.00K | $693.69M | $455.00K | $-622.32M | $71.83M | (m) | 3 month · $199.00K | 3 month · $1.27M | (m) | (m) |
| 2025-06-30 | $0.00 | $9.00K | $692.22M | $420.00K | $-590.78M | $101.87M | (m) | 3 month · $110.00K | 3 month · $1.05M | (m) | (m) |
| 2025-03-31 | (m) | $9.00K | $690.91M | $447.00K | $-574.92M | $116.44M | (m) | 3 month · $50.00K | 3 month · $909.00K | (m) | (m) |
| 2024-12-31 | $0.00 | $8.00K | $588.58M | $451.00K | $-618.01M | $-28.97M | (m) | 12 month · $504.00K | 12 month · $7.95M | (m) | (m) |
| 2024-09-30 | (m) | $8.00K | $585.37M | $577.00K | $-535.86M | $50.10M | (m) | 3 month · $139.00K 9 month · $426.00K | 3 month · $1.90M 9 month · $6.32M | (m) | (m) |
| 2024-06-30 | (m) | $8.00K | $583.33M | $494.00K | $-516.60M | $67.23M | (m) | 3 month · $138.00K 6 month · $287.00K | 3 month · $1.92M 6 month · $4.42M | (m) | (m) |
| 2024-03-31 | (m) | $7.00K | $580.97M | $476.00K | $-521.66M | $59.80M | (m) | 3 month · $148.00K | 3 month · $2.50M | (m) | (m) |
| 2023-12-31 | (m) | $7.00K | $578.33M | $545.00K | $-486.80M | $92.08M | (m) | 12 month · $853.00K | 12 month · $11.80M | (m) | (m) |
| 2023-09-30 | (m) | $4.00K | $513.23M | $497.00K | $-458.90M | $54.82M | (m) | 3 month · $326.00K 9 month · $708.00K | 3 month · $2.88M 9 month · $9.36M | (m) | (m) |
| 2023-06-30 | (m) | $0.00 | $510.00M | $497.00K | $-440.86M | $69.64M | (m) | 3 month · $222.00K 6 month · $382.00K | 3 month · $2.98M 6 month · $6.48M | (m) | (m) |
| 2023-03-31 | (m) | $4.00K | $506.32M | $499.00K | $-422.07M | $84.75M | (m) | 3 month · $161.00K | 3 month · $3.50M | (m) | (m) |
| 2022-12-31 | (m) | $4.00K | $502.61M | $401.00K | $-399.12M | $103.90M | (m) | 12 month · $1.29M | 12 month · $13.54M | (m) | (m) |
| 2022-09-30 | (m) | $4.00K | $499.08M | $159.00K | $-377.23M | $122.01M | (m) | 3 month · $219.00K 9 month · $1.11M | 3 month · $3.27M 9 month · $10.31M | (m) | (m) |
| 2022-06-30 | (m) | $4.00K | $495.54M | $50.00K | $-358.61M | $136.98M | (m) | 3 month · $447.00K 6 month · $891.00K | 3 month · $3.55M 6 month · $7.03M | (m) | (m) |
| 2022-03-31 | (m) | $4.00K | $491.37M | $204.00K | $-338.69M | $152.89M | (m) | 3 month · $444.00K | 3 month · $3.48M | (m) | (m) |
| 2021-12-31 | (m) | $4.00K | $487.35M | $452.00K | $-303.07M | $184.73M | (m) | 12 month · $795.00K | 12 month · $12.54M | (m) | 12 month · $-875.00K |
| 2021-09-30 | (m) | $4.00K | $482.62M | $-250.00K | $-265.36M | $217.01M | (m) | (m) | (m) | 3 month · $3.29M 9 month · $9.26M | 3 month · $-727.00K 9 month · $-727.00K |
| 2021-06-30 | (m) | $4.00K | $401.36M | $-251.00K | $-232.23M | $168.88M | (m) | (m) | (m) | 3 month · $3.21M 6 month · $5.96M | (m) |
| 2021-03-31 | (m) | $4.00K | $397.86M | $-227.00K | $-202.41M | $195.22M | (m) | (m) | (m) | 3 month · $2.76M | (m) |
| 2020-12-31 | (m) | $4.00K | $394.96M | $-188.00K | $-174.74M | $220.04M | (m) | (m) | (m) | 12 month · $2.98M | 12 month · $-4.12M |
| 2020-09-30 | (m) | $0.00 | $3.62M | $32.00K | $-140.32M | $-136.67M | (m) | (m) | (m) | 3 month · $1.02M 9 month · $1.67M | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-104.57M | (m) | (m) | (m) | 3 month · $327.00K 6 month · $658.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-83.94M | (m) | (m) | (m) | 3 month · $331.00K | (m) |
| 2019-12-31 | (m) | $0.00 | $1.42M | $-115.00K | $-66.20M | $-64.89M | (m) | (m) | (m) | 12 month · $752.00K | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-47.02M | (m) | (m) | (m) | 3 month · $151.00K 9 month · $604.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-33.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-13.75M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |